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Abstract 
 Over-expression of the folate receptor (FR) has been shown on the vascular side of cancerous 
cells including those of the breast, ovaries, testes, and cervix.  However, FR over-expression has not 
yet been explored fully in melanoma. We hypothesized that folate receptor is over-expressed on 
melanoma and that a novel folate-conjugated immunoglobulin G (F-IgG) would bind the FR to 
target melanoma cells for lysis by natural killer (NK) cells.  
 Folate receptor expression was confirmed in the Mel-39 (human melanoma) cell line by flow 
cytometry and immunoblot analysis, using KB (human oral epithelial) and F01 (human melanoma) 
as a positive and negative control, respectively. FR-positive and negative cell lines were coated with 
F-IgG or control immunoglobulin G (C-IgG) in the presence or absence of cytokines in order to 
determine NK cell ability to lyse FR-positive cell lines. NK cell activation was significantly  
upregulated and lysis of Mel 39 tumor cells enhanced following treatment with F-IgG, as compared 
to C-IgG at all effector:target (E:T) ratios (p<0.01). This trend was further enhanced by the addition 
of interleukin-12 (IL-12).  NK cell production of cytokines such as interferon-gamma (IFN-γ), 
macrophage inflammatory protein 1 alpha (MIP-1α), and regulated on activation normal T-cell 
expressed and secreted (RANTES) were also significantly increased in response to IL-12 stimulation 
and F-IgG-coated Mel 39  target cells, as compared to controls (p<0.01).  In contrast, F-IgG did not 
bind to F01 (FR-negative cell line) and had no significant effect on NK cell lysis or cytokine 
production. This research indicates the potential use of F-IgG for its ability to induce an immune 
response from NK cells against FR-positive melanoma tumor cells which can be further enhanced by 
the addition of cytokines.  
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Specific Aims 
Aim 1: To test the hypothesis that FR is expressed in melanoma cells lines. 
Rationale 1: It has been shown that FRs are over-expressed in various cancers, including cancers 
of the cervix, ovaries, breast, uterus, pituitary gland, lung, brain, and testes (3, 4). However, there 
is limited data indicating FR expression in melanoma tissue. Therefore, we propose to test if the 
FR is expressed in melanoma tumor cell lines.  In this specific aim, FR expression will be 
assessed utilizing reverse transcriptase polymerase chain reaction (RT-PCR) and immunoblot 
analysis, in vitro.  
Aim 2: To test the hypothesis that F-IgG binds to FR-positive melanoma cancer cells. 
Rationale 2: Our lab has demonstrated the ability of F-IgG to bind the FR in multiple cancer cell 
lines, in vitro. In this specific aim, we propose to examine the ability of F-IgG binds to 
melanoma tumor cell lines by utilizing flow cytometric analysis, in vitro.  
Aim 3: To test the hypothesis that F-IgG-coated melanoma tumor cells result in NK cell 
activation. 
Rationale 3: Our lab has demonstrated that F-IgG-coated human oral epithelial and murine 
leukemia tumor cells promote increased NK cell killing and cytokine secretion, as compared to 
C-IgG-coated tumor cells.  Therefore, it will be determined if F-IgG-treated melanoma tumor 
cells promote increased NK cell killing and cytokine secretion.  In this specific aim, the ability of 
F-IgG to enhance NK cell killing will be assessed utilizing antibody-dependent cell-mediated 
cytotoxicity (ADCC) and activation will be measured by enzyme-linked immunosorbent assay 
(ELISA) as well as flow cytometric analysis, in vitro.  
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Introduction 
Melanoma: Cutaneous melanoma (CM) arises from neural crest-derived epidermal melanocytes 
found next to the basal layer of the epidermis whose main role is the production of the pigment 
melanin (5).  The epidermis is only a thin layer of skin cells; however, it has a large role in 
protecting underlying cells and organs from exterior factors such as damaging ultraviolet light 
due to the presence of melanin (Figure 1).  
The genesis and development of melanoma 
has yet to be fully understood on a molecular 
basis; however, there have been many genetic 
mutations previously described that may result 
in its occurrence (6).  Consequentially, a 
wealth of information has yet to be gathered 
regarding CM and the way in which it grows 
and metastasizes.  
Additionally, mortality rates of people with CM have continued to climb despite 
increased awareness, research, and public education.  The World Health Organization has 
estimated there will be 120,000 new cases of CM per year internationally; this estimate has been 
on the rise (7). Presently, over 79% of skin cancer related deaths are attributed to CM and 
culminate in, on average, one American dying from CM almost every hour (8).  While a 
staggering number of people are expected to be diagnosed with CM yearly, few patients, such as 
those with metastasized melanoma or melanoma of the lymph node, will respond to surgical 
procedures or systematic therapy long term.  Melanoma cells appear to be fundamentally 
Figure 1. Dermis Layers (1). 
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resistant to previously proposed drugs, such as Temodar and Yervoy, as well as radiation 
therapy.  
 
Folate: Folate is a water soluble B vitamin used for cellular growth and associated processes.  
Specifically, folate functions as a co-factor in various cellular metabolic processes of the cell 
such as nucleic acid and protein biosynthesis.  Leafy green vegetables, legumes, egg yolks, and 
fresh fruit are natural sources of folate.  However, the common dietary source of folate is 
achieved through supplementation and food fortification, where the vitamin is present in its 
oxidized form known as folic acid (5, 9).  Additionally, folic acid is hypothesized to increase 
cancer cell motility, invasion, metastases and overall tumor progression (10-12).  
 
Folate receptor: Cellular folate uptake is mediated by at least three distinct transporters which 
include the reduced folate carrier (RFC), a proton-coupled high affinity folate transporter, and 
the folate receptor (FR) (13).  The RFC is a bidirectional low affinity transmembrane anion 
carrier that is the predominant folate transporter in most cells and is ubiquitously expressed on 
normal tissues.  The RFC will not transport folic acid (oxidized form) or folate conjugates (14).  
The second transporter of folate, the proton-coupled high affinity transporter, is a major folate 
transporter in low pH environments and appears to be the principal transporter in intestinal 
absorption of folate.  The FR is a membrane bound high affinity unidirectional folate transporter 
protein that characteristically binds folic acid, chemical conjugates of folic acid, as well as 
folate-linked immunological agents (8). The FR has three well-established isoforms, α, β, (both 
linked to glycosylphosphatidylinositol; GPI) and γ (15).   
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Specifically, in normal epithelial cells, the FR is located mainly on the luminal side of the 
cell and is consequentially largely inaccessible to circulating folate.  In contrast, the FR of 
malignant cells, such as lung, uterus, pituitary gland, cervix, ovaries, ependymal brain, and blasts 
of myeloid leukemias, is over-expressed on the extracellular side of the cell and therefore 
available to bind circulating folate (3, 16-22). This altered expression is not well understood, 
however, it is hypothesized that this occurs in order to supply higher levels of folate to malignant 
cells for enhanced cellular growth. Estimates suggest that roughly 1/3 of all cancers may involve 
the up-regulation of the FR, with metastatic and later-stage cancers associated with increased FR 
over-expression compared to the FR expression of non-malignant cells (23). 
 
Natural killer (NK) cells: NK cells are lymphocytes, a major component to the innate immune 
system, that defend the body against foreign substances.  They have the capacity to lyse 
malignant cells with altered expression of major histocompatibility antigens by virtue of their 
expression of killer cell immunoglobulin receptors (KIR).  They also express numerous cellular 
adhesion molecules, multiple receptors for stimulatory cytokines (i.e. interferon-gamma [IFN-γ], 
tumor necrosis factor-alpha [TNF-α], and macrophage inflammatory protein 1 alpha [MIP-1α]), 
possess cytolytic granules that contain perforin and granzymes, and produce cytokines with 
anti-tumor effects.  Additionally, NK cells express FcRIIIa, an activating receptor that 
recognizes the constant (Fc) region of Immunoglobulin G (IgG).  The FcγRIIIa receptor is 
critical in mediating antibody-dependent cell-mediated cytotoxicity (ADCC) against antibody 
(Ab)-coated targets (3, 24). 
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Figure 2. Simplified diagram of human antibody structure.(2) 
Constant region (Fc): IgG are 150kDa antibody 
molecules made of two heavy chains, two light chains 
and two different binding sites, as seen in Figure 2. 
Disulfide bonds hold together the heavy and light 
chains.  The end of each Fab region contains an 
antigen binding site whilst the Fc region of the 
molecule, also known as the constant region, is 
recognized by immune cells.  When treating FR-positive tumor cells with the folate-conjugated 
immunoglobulin G (F-IgG), the cell effectively becomes coated with IgG, allowing cells of the 
immune system with Fc receptors (FcR) to target the Fc portion of the IgG and destroy these 
cells.  Previous research has demonstrated that NK cells contain FcRs that bind antibody-coated 
cells and target them for killing via ADCC (25-28).  It is also well established that NK cells are 
crucial mediators of ADCC via perforin and granzyme lysis of tumor cells.  Furthermore, the 
interaction between NK cells and antibody-coated tumor cells has been demonstrated in vitro and 
in vivo and results in overall decreased tumor growth (29-36). 
 
Rationale for the use of a F-IgG conjugate: The FR has the potential to be exploited as a valid 
therapeutic target. This is due to its over-expression on tumor cells, as well as the fact that 
receptor endocytosis does not lead to lysosome-mediated destruction of folate-based 
therapeutics.  This allows the folate therapeutic to enter the cell and avoid destruction because of 
the requirement for folate by the cell (37).  The FR itself is efficiently recycled and returned to 
the cell surface, allowing for the re-uptake of additional folate and foltate conjugates.  These 
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parameters are thought to create a favorable toxicity profile for folate-conjugated anti-tumor 
compounds (4, 13, 37-40). 
The utilization of the FR has also been exploited in several other studies, which 
demonstrate the importance of this transport mechanism.  Other studies have targeted the FR 
utilizing multiple methods, such as monoclonal antibodies, folate-liposome loaded delivery and 
folate-FITC targeting (4, 41). This data, along with our own studies, support the development of 
FR-directed therapeutic immunoconjugates, where the FR serves as a ligand for cancer-specific 
targeting.   
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Materials and Methods 
Human F-IgG synthesis.  The technique for conjugating folate to macromolecules has been 
previously described (14, 42).  Folate was reacted with N, N’-dicyclohexylcarbodiimide (DCC) 
and N-hydroxysuccinimide (NHS) in DMSO at stoichiometric molar ratios of 1:1:1 for 3 hrs at 
room temperature.  The resultant product was filtered to remove precipitate.  Then activated 
folate (f-NHS) was reacted with IgG (Equitech-Bio Inc., Kerrville, TX) in pH 8.0 PBS buffer 
solution at a molar ratio of 12:1 for 2 hrs at room temperature.  After incubation, to remove 
unreacted f-NHS, the sample was passed through a PD-10 column equilibrated in PBS (pH 8.0).  
For the preparation of FITC labeled F-IgG (F-IgG-FITC) or IgG (IgG-FITC), activated f-NHS 
was reacted with IgG and FITC in pH 8.0 PBS buffer solution at a molar ratio of 12:1:5 for 2 hrs 
at room temperature.  The folate content of the construct was determined by UV spectrometry at 
371 nm and the antibody concentration was determined by the BCA protein assay method.  
Conjugation reactions performed at IgG-to-folate-NHS ratios of 12:1 and 100:1 yielded 
preparations containing an average molar ratio of 2.6 folate molecules per IgG molecule and 9.0 
folates per IgG, respectively. Since excessive folate conjugation may negatively affect the 
effector function of the IgG, a lower conjugation level of 3 folates per IgG was chosen for further 
study.  Unmodified human IgG molecules were used as controls (C-IgG).  Conjugates were 
stored at 4°C in the dark prior to use. 
Cell lines. The FR-positive human cell lines Mel-39 (human melanoma, ATCC) and KB (human 
oral epithelium, a gift from Dr. Philip S. Low, Purdue University, West Lafayette, Indiana), as 
well as the FR-negative cell line F01 (human melanoma) were propagated
 
in folate-free RPMI 
1640, supplemented with 10% heat-inactivated fetal bovine
 
serum (FBS), 1% 
antibiotic-antimycotic, and 0.1% plasmocin (Gibco). 
Skinner C.C. 
 
10 
 
Isolation of human NK cells.  NK cells were isolated directly
 
from fresh peripheral blood 
leukopacks (American Red Cross,
 
Columbus, OH) by 30-minute incubation with RossetteSep 
cocktail
 
(Stem Cell Technologies, Vancouver, BC) prior to Ficoll Hypaque
 
(Sigma) density 
gradient centrifugation.  Human NK cells were cultured in folate-free RPMI 1640 (purchased 
from The Cleveland Clinic Media Preparation Service, Cleveland, OH) supplemented with
 
10% 
heat-inactivated pooled human AB serum (HAB; C-Six Diagnostics,
 
Germantown, WI) and 1% 
antibiotic-antimycotic.
 
Reverse Transcription Polymerase Chain reaction (RT-PCR) for FR-α and FR-β 
expression.  Total RNA from Mel 39, KB, and F01 cells was extracted in TRIZOL
® 
Reagent 
using the RNeasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer’s protocol.  RNA 
was converted to complementary DNA by reverse transcription and used as a template for 
RT-PCR using FR-α (forward primer, TGGGTGGCTGTAGTAGGGGAG; reverse primer, 
CAGGGGCACGTTCAGTACC) and FR-β primers (forward primer, ACCAATGCAGTCC-
CTGGAAGAAGA; reverse primer, AGCTGGGCACTTGTTAACTCCTGA)  (33).  The PCR 
conditions consisted of 95°C for 30s followed by 30 cycles of 95°C for 30s, 58°C for 30s, and 
72°C for 40s.   
Flow Cytometric Analysis. The FR-positive cell lines, Mel 39 and KB, or the FR-negative cell 
line, F01, were grown in folate-free RPMI 1640, supplemented with 10% heat-inactivated fetal 
bovine
 
serum (FBS), 1% antibiotic-antimycotic, and 0.1% plasmocin.  1 x 10
6
 cells were 
resuspended in 500 µL
 
of media in flow tubes and stained with 20 µg of C-IgG-FITC or 
F-IgG-FITC. Cells were incubated for 1-hr at 4°C, washed with 1mL PBS with 1% TBST (flow 
buffer) at 1700 rpm for 10 min. Cells were then fixed with 300 µl of 1% formalin in PBS after 
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aspirating the supernatant and examined via flow cytometric analysis, as previously described 
(32). 
Cytotoxicity assays.  Purified human NK cells were plated in 96-well V-bottom plates
 
in 10% 
HAB containing folate-free RPMI 1640 medium supplemented with interleukin-12 (IL-12) (10 
ng/mL), and incubated
 
overnight at 37°C.  For
 
ADCC assays, F-IgG or C-IgG-treated (100 
ug/mL) 
51
Cr-labeled target cells were
 
added to NK cells at different effector:target (E:T) ratios. 
Following a 4-hr incubation
 
at 37°C, supernatants were harvested for quantification
 
of chromium 
release.  Percentage of lysis was determined as
 
previously described (35).   
In vitro co-culture assay.  The FR-positive cell lines, Mel 39 and KB, or the FR-negative cell 
line, F01, were cultured in the wells of a 96-well flat-bottom culture plate overnight at 37°C, as 
previously described (29). Briefly, the culture supernatant
 
was aspirated the following day and 
wells were treated with
 
100 µg/mL F-IgG or C-IgG for 1 hr at 37°C.  After washing off unbound 
F-IgG or C-IgG, purified
 
NK cells were then added at 2 x 10
5
 cells per well in 200 µL
 
of folate 
free RPMI containing 10% HAB medium and 10 ng/mL IL-12.  Control
 
conditions consisted of 
NK cells plus tumor cells treated with
 
medium alone, F-IgG or C-IgG alone, or cytokine alone.
 
  
Culture
 
supernatants were harvested after 48 hours and analyzed for IFN-, MIP-1α, and 
regulated upon activation, normal T-cell expressed and secreted (RANTES) content by 
enzyme-linked immunosorbent assay (ELISA).  All
 
results shown are the mean of triplicate wells 
± SD. Purified NK cells were co-cultured with Mel 39 tumor cells and collected after 48 hours, 
then examined for activation. Harvested NK cells were incubated with mouse-anti-human 
CD56-APC and CD69-PE antibodies (BD Pharmingen) as directed by the manufacturer.   
Samples were then washed with flow buffer and fixed in 1% formalin in PBS and assessed via 
flow cytometric analysis as previously described (32). 
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Statistics.  These experiments tested whether there were significant effects with F-IgG alone and 
synergistic effects with IL-12 on NK cell mediated ADCC and cytokine production.  A student’s 
t-test and an analysis of variance (ANOVA) were utilized for two-way and multiple 
comparisons, respectively.  
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Results 
The FR is expressed on melanoma tumor cell lines. 
To evaluate whether F-IgG has a FR to bind to, we analyzed the expression of the FR on various 
melanoma cell lines via RT-PCR and western blot analysis.  RT-PCR was used for its ability to 
provide confirmation of the presence of FR RNA 
sequences.  Western blot analysis allowed for the 
characterization of FR protein content of the various 
malignant cell lines.  FR was over-expressed on Mel 39 
(human melanoma) and KB (human oral epithelial), but 
not on F01 (human melanoma) malignant cell lines via 
both RT-PCR and Western blot analyses (Figure 3A-B).  
The KB and F01 tumor cells lines served as positive and 
negative controls, respectively. It is important to note 
that, as seen by the F01 cell line, that not all melanoma 
express a FR + profile. 
 
F-IgG binds to FR-positive melanoma tumor cells. 
It was hypothesized that F-IgG binds to FR-positive melanoma tumor cell lines with great 
affinity. Flow cytometry was utilized to assess binding of F-IgG. Here, a F-IgG-FITC conjugate 
was utilized. This method 
was used for its ability to 
demonstrate the presence 
of the FR on the surface of 
Figure 3. FR expression in melanoma cell lines. 
(A)Western Blot and (B) PCR analyses of FR 
expression in melanoma cell lines. 
Figure 4. F-IgG binds FR (blue) in melanoma cell lines. (A) Flow cytometric analyses 
of F-IgG binding to FR in melanoma cell lines. 
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the various malignant cell types and to determine if the F-IgG conjugate binds to the surface of 
these cells. The Mel 39 and KB cell lines were >97% FR-positive, as indicated by F-IgG-FITC 
flow cytometry.  This was not observed with the FR-negative cell line F01, which was <1% FR-
positive (Figure 4).   
 
NK cells are activated by F-IgG coated FR-positive melanoma tumor cells. 
It was hypothesized that NK cells would be 
activated in response to F-IgG coated FR-positive 
melanoma cell lines. To determine the ability of 
F-IgG enhancement of NK cell activation, ADCC 
and ELISA assays were utilized, in vitro. In support 
of this hypothesis, it was found that F-IgG coated 
FR-positive cell lines resulted in NK-cell mediated 
ADCC. A four-hour 
51
Cr-release assay was utilized, 
where malignant cells were labeled with the 
radioactive isotope, coated with the F-IgG, then 
exposed to NK cells at different effector:target (E:T) 
ratios. During this experiment, NK cells served as 
effector cells and Mel 39, KB, or F01 served as the targets. NK cell lysis of F-IgG-coated Mel 39 
target cells was significantly enhanced, as compared to C-IgG (p<0.01). This was further 
increased following treatment of NK cells with IL-12 (10ng/mL).  IL-12 activated NK cells lysed 
50+5% F-IgG-coated Mel 39 tumor cells as compared to <20% lysis for the control groups 
Figure 5. F-IgG coated FR-positive melanoma cells 
activate NK cells. (A) Four-hour 51Cr-release release 
ADCC results for NK cell lysis of F-IgG+IL-12, 
C-IgG+IL-12, F-IgG, or C-IgG coated KB tumor cells. 
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(Figure 5A-B). Notably, the FR-negative cell line, F01, demonstrated < 20% lysis for all 
treatment groups (data not shown).  
NK cell activation was also assessed by cytokines secreted in this setting. Here, NK cells 
were exposed to F-IgG coated melanoma tumor cells. NK cell production of IFN-γ, RANTES, 
and MIP1-α was significantly 
enhanced in response to 
F-IgG-coated Mel 39 target cells, as 
compared to C-IgG (p<0.01).  This 
effect was further enhanced by IL-12. 
IL-12 activated NK cells exposed to 
F-IgG-coated FR-positive melanoma 
tumor cells produced 7100 pg/mL 
IFN-gamma at 72 hours as opposed to < 1200 pg/mL for the control conditions (C-IgG, C-IgG + 
IL-12, or F-IgG). Similarly, the NK cell production 
of RANTES and MIP1-alpha was significantly and 
synergistically enhanced by FIgG alone and F-IgG 
+ IL-12, respectively (p<0.01) (Figure 6 A-C).  
NK cell activation was further 
demonstrated by changes in NK cell surface 
markers.  C-IgG or F-IgG coated Mel-39, F01, and 
KB tumor cells were co-cultured with and without 
IL-12 stimulated NK cells in a 96-well plate.  After 
48 hours, cells were harvested and stained for 
Figure 6. NK cell IFN-γ (A), RANTES (B), and MIP1-α (C) cytokine 
secretion in response to C IgG and F-IgG coated tumor cells. 
Figure 7. NK cells are activated in response to F-IgG and F-IgG+IL-12. 
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CD56+ (identifying NK cells) and CD69+ surface markers to assess NK cell activation.  NK 
cells co-cultured with KB and Mel 39 had increased NK cell activation, with the greatest 
activation following dual stimulation. This trend was not observed with the FR-negative, F01, 
melanoma cell line (Figure 7). 
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Discussion  
Previous studies involving the FR have indicated the presence of FR in many cancers, 
including those of the ovaries, breast, and cervix (9). These studies also noted the potential 
exploitation of FR over-expression in possible cancer therapeutics. The presence of FR in human 
melanoma, however, has not been fully characterized or defined.  This study determined the 
presence of FR in melanoma tumor cell lines in order to assess the potential therapeutic 
application of a F-IgG conjugate in this setting.  
Here, it was found that FR over-expression was significantly higher in the Mel 39 
melanoma cell line, compared to other non-malignant cell lines. This indicates the opportunity to 
exploit the FR as a selective target for melanoma.  Other melanoma cell lines will be explored by 
our laboratory, as this would be necessary to test the statistical significance of the observation 
that the FR is over-expressed in melanoma cell lines. 
These results indicate that F-IgG is able to bind to FR-positive Mel 39 melanoma tumor 
cells. This data demonstrates the potential use of F-IgG as a selective therapeutic in melanoma as 
well as other FR-positive cancers cell lines.  Since FR over-expression has been correlated with 
malignancy, this potential therapeutic allows for the selective targeting of FR-positive melanoma 
cells as compared to other nonmalignant cells present. 
Furthermore, we demonstrate that F-IgG coated FR-positive melanoma cell lines are able 
to stimulate an immune response through NK cell-mediated ADCC and enhanced activation.  
Specifically, increased tumor cell killing might occur in an in vivo setting where there may be a 
more significant anti-tumor immune response at the tumor site.  NK cell cytokine secretion will, 
in turn, support the infiltration of other immune cells via the enhanced NK cell cytokine 
production observed. IFN-γ, MIP1-α, and RANTES are well known inflammatory cytokines that 
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are involved in mediating the migration of various immune cells which are integral to the anti-
tumor response in an in vivo setting (31).   
From the results of our study we conclude that FR over-expression is found in Mel 39 
melanoma tumor cells and that F-IgG is able to bind to these cells and stimulate an immune 
response which is further enhanced by IL-12 addition.  
 
Significance 
Research into FR expression on melanoma cells is critical in the development of selective 
targeting of malignant cells with minimal effects on nonmalignant cells.  With the data obtained 
in this study, the potential use of F-IgG as an anti-tumor compound has been supported due to 
the ability of F-IgG to stimulate an anti-tumor response in FR-positive melanoma cell lines. The 
observations of this study provide a greater understanding of this possible therapy and its effects 
on NK cells which may next be translated into an animal model and eventually the clinic. 
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